Clinical Trial Update: 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line treatment for unresectable colorectal cancer with KRAS G12C mutation using a combination of 5-fluorouracil, panitumumab and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Panitumumab (Vectibix) (panitumumab)
• Sotorasib (Lumakras) (sotorasib)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Colorectal Carcinoma, KRAS G12C Mutation | Phase 2 | Status: NOT_YET_RECRUITING